Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.
Pfizer Inc. (PFE) is a global biopharmaceutical leader driving innovations in vaccine development and therapeutic treatments. This news hub provides investors and industry professionals with timely updates on corporate developments, regulatory milestones, and market strategies.
Access official press releases, earnings reports, and analysis of Pfizer's clinical trial progress. Our curated collection covers FDA approvals, partnership announcements, and research breakthroughs across oncology, immunology, and infectious disease portfolios.
Key updates include quarterly financial results, manufacturing expansions, and strategic collaborations shaping the pharmaceutical landscape. Bookmark this page for reliable insights into one of healthcare's most influential companies, with content organized for efficient navigation across devices.
Pfizer Inc. (NYSE: PFE) reported that the
Pfizer Inc. (NYSE: PFE) has appointed Aamir Malik as the new Executive Vice President and Chief Business Innovation Officer, effective August 30, 2021. Malik, previously a Managing Partner at McKinsey & Company, will report to CEO Albert Bourla and succeed John Young as he retires after 34 years. In his new role, Malik will be responsible for the company’s strategy, business development, and innovative partnerships globally. Bourla highlighted Malik's extensive experience in driving growth and improving patient care during the announcement.
Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have signed a letter of intent with Eurofarma Laboratórios SA to manufacture their COVID-19 vaccine, COMIRNATY®, for distribution in Latin America. Eurofarma will initiate technical transfer and on-site development immediately, with finished dose production expected to exceed 100 million doses annually, beginning in 2022. This collaboration aims to enhance equitable access to vaccines in the region, contributing to a total of 3 billion doses planned for global distribution by year-end 2021.
Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) announced the initiation of a supplemental Biologics License Application for a third dose of COMIRNATY. New Phase 3 trial data show the booster dose significantly increases SARS-CoV-2 neutralizing antibody titers, achieving levels 3.3 times higher than the second dose. The companies plan to submit these findings to the European Medicines Agency and other regulatory bodies shortly. Adverse events observed were mild to moderate, with a low incidence of severe reactions, consistent with previous clinical data.
Pfizer and BioNTech received FDA approval for COMIRNATY®, making it the first FDA-approved COVID-19 vaccine for individuals aged 16 and older. This vaccine has been available under Emergency Use Authorization since December 2020. The approval validates the vaccine's efficacy and safety, supported by long-term Phase 3 trial data. Approximately 60% of eligible Americans are fully vaccinated, and the companies aim to enhance vaccine confidence. COMIRNATY is also authorized for individuals aged 12-15 under EUA and will seek further approvals for booster doses and younger age groups.
Pfizer (NYSE: PFE) has announced its definitive agreement to acquire Trillium Therapeutics (NASDAQ/TSX: TRIL) for an equity value of $2.26 billion, equating to $18.50 per share, marking a significant 118% premium. The acquisition aims to enhance Pfizer's oncology portfolio, especially in treating blood cancers, by integrating Trillium's lead molecules, TTI-622 and TTI-621, which target the SIRPα-CD47 axis. These molecules are in advanced clinical trials and show promise as therapies for various hematological malignancies.
Pfizer Inc. (NYSE: PFE) has received approval from the European Commission for XELJANZ® (tofacitinib) for treating active polyarticular juvenile idiopathic arthritis (JIA) and juvenile psoriatic arthritis (PsA) in patients aged two years and older who have not responded adequately to previous disease-modifying antirheumatic drug (DMARD) therapies. The approval includes a new oral solution and a once-daily tablet formulation. XELJANZ is the first JAK inhibitor approved in Europe for these indications and has been studied across over 50 clinical trials globally.
Pfizer (PFE) and BioNTech (BNTX) have submitted Phase 1 data to the FDA for a booster dose of their COVID-19 vaccine (BNT162b2). This submission follows successful Phase 1 trials showing significantly higher neutralizing antibodies after a third dose compared to the two-dose schedule. The companies plan to also submit this data to the EMA and other authorities soon. Although the booster is not yet widely authorized in the U.S., it was recently approved for immunocompromised individuals. Further Phase 3 results are expected shortly.
Pfizer Inc. (NYSE:PFE) has received FDA approval for TICOVAC™, a vaccine for tick-borne encephalitis (TBE), aimed at individuals aged 1 and older. This makes TICOVAC™ the first FDA-approved vaccine to protect U.S. residents traveling to TBE-endemic areas. With over 170 million doses distributed globally over the past 45 years, the vaccine shows a seropositivity rate of 99.5% in children and 98.7-100% in adults after three doses. While TBE is not endemic in the U.S., it poses significant health risks in over 35 countries worldwide.
